Owlet (OWLT) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
14 Jan, 2026Executive summary
Q3 2024 revenue reached $22.1 million, a 141% year-over-year increase, driven by strong Dream Sock sales and higher consumer demand across all channels.
Gross margin improved to 52.2%, up 1,590 basis points from Q3 2023, reflecting favorable product mix, lower costs, and reduced return rates.
Adjusted EBITDA was $0.6 million, a $6.1 million improvement year-over-year, marking the second consecutive quarter of positive Adjusted EBITDA.
Net loss for Q3 2024 was $5.6 million, flat year-over-year, while operating loss narrowed to $4.8 million from $7.9 million.
Completed follow-on equity and preferred stock offerings, raising $9.8 million and $8.9 million, and entered new credit facilities to strengthen liquidity.
Financial highlights
Q3 2024 net revenue: $22.1 million, up 141% year-over-year; gross profit: $11.5 million; gross margin: 52.2%.
Adjusted EBITDA: $0.6 million (Q3 2024), a $6.1 million improvement year-over-year.
Operating loss was $4.8 million, improved from $7.9 million last year; net loss remained at $5.6 million.
Cash and equivalents at quarter end: $21.5 million, up from $15.4 million in Q2 and $16.6 million at year-end 2023.
Operating expenses were $16.4 million, including $2.7 million stock-based compensation and a $1.9 million impairment charge.
Outlook and guidance
Full-year 2024 net revenue expected at $74–$77.5 million, gross margin 48–49%, Adjusted EBITDA loss $5–$3 million.
Management highlights ongoing liquidity risks and the need for additional financing to support operations and growth.
Company regained compliance with NYSE listing standards but remains under a 12-month follow-up period.
Latest events from Owlet
- Up to 9.6 million shares registered for resale by major holders; no proceeds to the company.OWLT
Registration Filing10 Mar 2026 - Record revenue, margin, and subscriber growth; strong 2026 outlook with global and AI expansion.OWLT
Q4 20255 Mar 2026 - Q1 revenue up 43% with record margin, breakeven EBITDA, and raised guidance amid ongoing risks.OWLT
Q1 20253 Feb 2026 - Dual FDA clearances and strong retail momentum position the company for rapid growth and margin expansion.OWLT
TD Cowen’s 8th Annual Future of the Consumer Conference1 Feb 2026 - Q2 revenue up 58% to $20.7M, gross margin 50%, but going concern risk remains.OWLT
Q2 20241 Feb 2026 - Record 2024 results, new FDA-cleared products, and margin gains set up for 2025 profitability.OWLT
Q4 202426 Dec 2025 - Proposes up to $100M in securities offerings to fund digital infant health solutions amid key risks.OWLT
Registration Filing16 Dec 2025 - Resale registration for 750,000 shares tied to a term loan, with no proceeds to the company.OWLT
Registration Filing16 Dec 2025 - Registration enables major investors to resell 5.3M shares, with no proceeds to the company.OWLT
Registration Filing16 Dec 2025